Skip to content

America’s Largest Drug Cartels Exposed – Pharmacy Benefit Managers


When plunder becomes a way of life for a group of men in a society, over the course of time they create for themselves a legal system that authorizes it and a moral code that glorifies it. ― Frédéric Bastiat

Tackling Rising Drug Prices in America

Americans can no longer afford to get sick and there’s a reason why.

Before entering public service at the federal level, I spent most of my life serving my community in a different way. As a pharmacist for more than 30 years, I saw firsthand the impact that prescription drug prices have on everyday citizens and families.

As a result of research and development I have seen improvements in medications that save lives. Illnesses that were once a death sentence are now treatable with a prescription. While this is nothing short of a miracle, these advances are worthless if they are not affordable.

I have seen elderly couples forced to choose between their medications and groceries. I’ve seen mothers struggle to afford their children’s prescriptions. That is what drives me to utilize my background as the only pharmacist in Congress to tackle rising drug prices in America.

To lower costs, there must be transparency, choice, competition and accountability in the health care supply chain. Unfortunately, instead, big business has wedged itself between patients and their health care in a dangerously opaque manner. The most egregious example of this is the middle man in the chain – the Pharmacy Benefit Managers.

Today, the three largest PBMs manage drug benefits for approximately 95% of Americans with prescription drug coverage.

The intent of Pharmacy Benefit Managers has evolved from negotiating prescription prices to a multi-billion dollar revenue machine that relies on a complicated system of rebates, formularies with no basis in health outcomes, and preferred networks. The result is fewer choices and less control for patients.

The largest Pharmacy Benefit Manager makes more than McDonalds, Pfizer, and Ford combined. At the same time, as they continue to advocate that they reduce expenses for patients, data from the Centers for Medicare and Medicaid Services shows out-of-pocket costs for patients increased 169% from 1987 to 2014.

The complex system of rebates and fees developed by Pharmacy Benefit Managers has eliminated any incentive to reduce costs. Even worse, it has created perverse incentives to drive costs up.

For example, pharmaceutical companies are often instructed to set a higher list price to deliver a rebate to the Pharmacy Benefit Manager. If they refuse, the Pharmacy Benefit Manager simply excludes the medication from their formulary. This is the definition of putting profit over patient as it cuts off access to new treatments. Additionally, those rebates, which were intended to drive down costs for patients, can actually add to them, creating an incentive for a higher list price.

As Health and Human Services Secretary Alex Azar said, “everybody is wetting their beak on a percent of a high list price, and we’ve got to change those dynamics.”

The other end of the drug chain is also trapped under the Pharmacy Benefit Manager’s web and I have experienced it firsthand. When a pharmacist attempts to negotiate contracts to provide the best for their patients, Pharmacy Benefit Managers often say contracts are non-negotiable. Pharmacists are left to either accept the Pharmacy Benefit Manager’s terms or be kicked out of network.

Even more shocking, pharmacists are many times contractually prohibited by Pharmacy Benefit Managers from telling their patients when it would be cheaper to pay with cash instead of insurance. I have experienced this and I am grateful President Trump has made eliminating this unfair practice a priority in his quest to lower prices.

Another concern is the alarming amount of consolidation in the market. As the discussion of consolidation continues, it has been abundantly clear that this message is resonating as people grapple with drivers of health care costs. On July 27th, the Energy & Commerce Committee sent a letter to the Federal Trade Commission outlining concerns with the potential effects on the consumer market. The goal is to ensure that mergers are in the best interests of patients and proper diligence is afforded to the review process.

An opinion piece recently published by this outlet falsely claimed that campaign donations from PhRMA is what is driving my work. Unfortunately for the author, if you simply follow the link provided by them, it clearly lays out that neither PhRMA nor any of their members are in my top 25 contributors. Community pharmacists who have dedicated their lives to serving patients across the country take that spot. They are the people who have seen Americans struggle and sacrifice across the country to afford their medications firsthand, just as I have.

I believe every part of the chain has a role to play in lowering prices and has a responsibility to do so. As part of this, we must demand transparency from Pharmacy Benefit Managers and shed light on anti-competitive practices that are not in the best interest of patients. This will have a direct and significant impact to lower costs for patients who need it the most. It is unfortunate that the author has attacked me for this mission and fails to see its necessity while claiming to be working against “abusive, monopolistic behavior.”

I look forward to continued work with my colleagues in Congress, President Trump and his administration to make this happen. Secretary Azar said we need to “fundamentally examine and re-examine the role of Pharmacy Benefit Managers.” We will work together to do just that.

[Byline Congressman Earl L. “Buddy” Carter]

Rep. Earl L. “Buddy” Carter, a Republican, represents Georgia’s First Congressional District. He is the only pharmacist currently serving in Congress.

Townhall (edited)
06 September 2018


Politicians and their corporate counter-parts have made lucrative careers out of manipulating the public, controlling subordinates, inciting fear and scaring off their competition.

Government bullying and psychological warfare are just several aspects of the seedier side of their business, and without at least an awareness of how they operate, the uninformed citizen is destined to perish among the sharks. Anyone can point out the importance of professional ethics, but at the end of the day, they aren’t going to do anything to help them overcome a tenacious domestic enemy, the one who won’t stop at anything in order to get what they want.


US prices soaring for some generic drugs

Market forces are dramatically driving up the cost of some generic drugs, prompting U.S. investigations into the pricing of what should be cheap alternatives to brand-name medications.


In response to these increases, both the U.S. Senate and the U.S. Department of Justice have undertaken investigations into generic drug pricing. Federal prosecutors have issued subpoenas to two generic drug makers, seeking information about possible collusion between competitors, according to a published report. At the same time, the Senate Subcommittee on Primary Health and Aging has sent letters to executives of 14 pharmaceutical companies asking for answers, and on Nov. 20 will hold a hearing into the matter.


One big reason U.S. health care costs are so high: pharmaceutical spending. The U.S. spends more per capita on prescription medicines and over-the-counter products than any other country. –Laurie Meisler

Financial Tyranny: “We the People” Are the New Permanent Underclass in America

Isn’t it obvious now, how this is working out?

Leave a Comment

Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s